[{"orgOrder":0,"company":"Hempstreet","sponsor":"MGC Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Partnership","leadProduct":"Artemisinin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Hempstreet","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Spray","sponsorNew":"Hempstreet \/ MGC Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Hempstreet \/ MGC Pharma"},{"orgOrder":0,"company":"Hempstreet","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Jatamansi","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Hempstreet","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hempstreet \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hempstreet \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Hempstreet

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Sarpagandha Vati’s diuretic and detoxifying properties benefit people with lifestyle issues, epilepsy, delirium, anxiety disorder, curbs desire for alcohol and induces natural sleep to defy Insomnia.

                          Brand Name : Sarpagandha Ghan Vati

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          August 23, 2022

                          Lead Product(s) : Sarpagandha,Khurasani Ajwain,Jatamansi

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Through this partnership, and through HempStreet’s extensive distribution reach and key institutional partnerships, Indian patients will now have access to these medicines, starting with CimetrA (Artemisinin), which had an immediate need.

                          Brand Name : CimetrA

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          May 07, 2022

                          Lead Product(s) : Artemisinin,Curcumin,Boswellia Serrata

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : MGC Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank